their disease. Although the more aggressive approach to the use of these drugs does offer the patient a better chance of significant visual improvement at least in the short term, this is often associated with severe systemic side-effects in both the young and older patient.
Cyclosporin has become a very useful second-line agent as a steroid sparer in those patients who can tolerate it. However, it is not suitable for or effective in everyone and the other currently available drugs are often of limited effectivity or associated with major systemic sequelae. This paper summarises the thera peutic approaches currently being examined to define whether they have a role in the better management of these patients in the future. Particularly exciting is the potential for sustained intraocular drug delivery so that adequate drug levels are achieved inside the eye without the necessity for systemic administration.
Uveitis remains a major cause of significant visual loss in the Western world.1 Sight-threatening com plications such as cataracf and glaucoma3 can now be managed much more effectively and safely in these patients but macular oedema, often causing profound loss of central vision, may or may not respond to conventional therapy. Posterior uveitis, which may or may not be associated with a systemic disease, is known to be a T-cell-mediated autoim mune disease.4 Current management consists of suppressing the immune system so as to dampen the inflammatory response, using either locally administered or systemic drugs. Corticosteroids remain the mainstay of treatment and can be given via the orbital floor or sub-Tenon's route in a depot preparation,S or systemically either as an intravenous bolus or orally. In many patients, the inflammatory response is quietened and additional therapy is not required. Additional therapy is required when 
NEW DRUG THERAPIES IN CLINICAL USE

Methotrexate
Methotrexate (MTX) is now used as a second-line drug for rheumatoid arthritis and juvenile chronic arthritis in many centres but at a much lower dose than when used previously. Its exact mode of action at this low dose remains uncertain, but its anti proliferative effect is thought to be important.8.9 At low doses given in a one dose weekly pulse (12.5 mg/ week or less), it is associated with few serious side effects. In the first ocular study, 12 patients with chronic non-infectious intraocular inflammatory dis ease, who had not responded to or who had become intolerant of corticosteroid or alternate cytotoxic agents, were treated weekly with oral low-dose pulse 
NEWER DRUG THERAPIES UNDER EVALUATION
Intraocular Steroid
Steroids are given to patients with uveitis by a variety of routes and intraocular steroid is often used per 
